Annual EBITDA
-$23.73 M
+$45.58 M+65.76%
December 31, 2023
Summary
- As of February 6, 2025, XERS annual EBITDA is -$23.73 million, with the most recent change of +$45.58 million (+65.76%) on December 31, 2023.
- During the last 3 years, XERS annual EBITDA has risen by +$55.39 million (+70.00%).
- XERS annual EBITDA is now -81.31% below its all-time high of -$13.09 million, reached on December 31, 2016.
Performance
XERS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$8.15 M
-$5.01 M-159.78%
September 30, 2024
Summary
- As of February 6, 2025, XERS quarterly EBITDA is -$8.15 million, with the most recent change of -$5.01 million (-159.78%) on September 30, 2024.
- Over the past year, XERS quarterly EBITDA has dropped by -$5.83 million (-250.93%).
- XERS quarterly EBITDA is now -250.93% below its all-time high of -$2.32 million, reached on September 30, 2023.
Performance
XERS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$23.07 M
-$5.83 M-33.82%
September 30, 2024
Summary
- As of February 6, 2025, XERS TTM EBITDA is -$23.07 million, with the most recent change of -$5.83 million (-33.82%) on September 30, 2024.
- Over the past year, XERS TTM EBITDA has increased by +$2.72 million (+10.54%).
- XERS TTM EBITDA is now -400.24% below its all-time high of -$4.61 million, reached on March 31, 2017.
Performance
XERS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
XERS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +65.8% | -250.9% | +10.5% |
| 3 y3 years | +70.0% | -250.9% | +10.5% |
| 5 y5 years | +58.5% | -250.9% | +10.5% |
XERS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +79.1% | -250.9% | +83.0% | -33.8% | +81.5% |
| 5 y | 5-year | at high | +79.8% | -250.9% | +83.0% | -33.8% | +81.5% |
| alltime | all time | -81.3% | +79.8% | -250.9% | +83.0% | -400.2% | +81.5% |
Xeris Biopharma Holdings EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$8.15 M(+159.8%) | -$23.07 M(+33.8%) |
| Jun 2024 | - | -$3.14 M(-62.8%) | -$17.24 M(-30.3%) |
| Mar 2024 | - | -$8.43 M(+151.6%) | -$24.73 M(+4.2%) |
| Dec 2023 | -$23.73 M(-65.8%) | -$3.35 M(+44.2%) | -$23.73 M(-7.9%) |
| Sep 2023 | - | -$2.32 M(-78.1%) | -$25.78 M(-33.2%) |
| Jun 2023 | - | -$10.63 M(+42.9%) | -$38.57 M(-19.6%) |
| Mar 2023 | - | -$7.44 M(+37.8%) | -$47.96 M(-29.6%) |
| Dec 2022 | -$69.31 M(-39.0%) | -$5.40 M(-64.3%) | -$68.09 M(-38.5%) |
| Sep 2022 | - | -$15.11 M(-24.5%) | -$110.79 M(-7.3%) |
| Jun 2022 | - | -$20.01 M(-27.4%) | -$119.57 M(-4.3%) |
| Mar 2022 | - | -$27.57 M(-42.7%) | -$124.95 M(+9.9%) |
| Dec 2021 | -$113.67 M(+43.7%) | -$48.09 M(+101.3%) | -$113.67 M(+38.0%) |
| Sep 2021 | - | -$23.89 M(-6.0%) | -$82.39 M(+14.8%) |
| Jun 2021 | - | -$25.40 M(+56.0%) | -$71.79 M(+5.5%) |
| Mar 2021 | - | -$16.28 M(-3.2%) | -$68.04 M(-14.0%) |
| Dec 2020 | -$79.12 M | -$16.82 M(+26.6%) | -$79.12 M(-15.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$13.29 M(-38.6%) | -$93.93 M(-14.3%) |
| Jun 2020 | - | -$21.65 M(-20.9%) | -$109.63 M(-9.5%) |
| Mar 2020 | - | -$27.36 M(-13.5%) | -$121.08 M(+2.8%) |
| Dec 2019 | -$117.80 M(+105.9%) | -$31.63 M(+9.1%) | -$117.80 M(+11.8%) |
| Sep 2019 | - | -$28.99 M(-12.4%) | -$105.36 M(+16.6%) |
| Jun 2019 | - | -$33.10 M(+37.5%) | -$90.39 M(+29.8%) |
| Mar 2019 | - | -$24.08 M(+25.5%) | -$69.64 M(+21.7%) |
| Dec 2018 | -$57.22 M(+117.3%) | -$19.19 M(+36.8%) | -$57.22 M(+21.6%) |
| Sep 2018 | - | -$14.03 M(+13.6%) | -$47.07 M(+16.2%) |
| Jun 2018 | - | -$12.35 M(+6.0%) | -$40.52 M(+21.4%) |
| Mar 2018 | - | -$11.65 M(+28.9%) | -$33.37 M(+26.7%) |
| Dec 2017 | -$26.33 M(+101.1%) | -$9.04 M(+21.0%) | -$26.33 M(+52.3%) |
| Sep 2017 | - | -$7.47 M(+43.8%) | -$17.28 M(+76.2%) |
| Jun 2017 | - | -$5.20 M(+12.7%) | -$9.81 M(+112.7%) |
| Mar 2017 | - | -$4.61 M | -$4.61 M |
| Dec 2016 | -$13.09 M | - | - |
FAQ
- What is Xeris Biopharma Holdings annual EBITDA?
- What is the all time high annual EBITDA for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings annual EBITDA year-on-year change?
- What is Xeris Biopharma Holdings quarterly EBITDA?
- What is the all time high quarterly EBITDA for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings quarterly EBITDA year-on-year change?
- What is Xeris Biopharma Holdings TTM EBITDA?
- What is the all time high TTM EBITDA for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings TTM EBITDA year-on-year change?
What is Xeris Biopharma Holdings annual EBITDA?
The current annual EBITDA of XERS is -$23.73 M
What is the all time high annual EBITDA for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high annual EBITDA is -$13.09 M
What is Xeris Biopharma Holdings annual EBITDA year-on-year change?
Over the past year, XERS annual EBITDA has changed by +$45.58 M (+65.76%)
What is Xeris Biopharma Holdings quarterly EBITDA?
The current quarterly EBITDA of XERS is -$8.15 M
What is the all time high quarterly EBITDA for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high quarterly EBITDA is -$2.32 M
What is Xeris Biopharma Holdings quarterly EBITDA year-on-year change?
Over the past year, XERS quarterly EBITDA has changed by -$5.83 M (-250.93%)
What is Xeris Biopharma Holdings TTM EBITDA?
The current TTM EBITDA of XERS is -$23.07 M
What is the all time high TTM EBITDA for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high TTM EBITDA is -$4.61 M
What is Xeris Biopharma Holdings TTM EBITDA year-on-year change?
Over the past year, XERS TTM EBITDA has changed by +$2.72 M (+10.54%)